Subject's freedom from device or procedure related death and/or reoperation at 1-year post-implant. Time to events were estimated by Kaplan-Meier method. A higher number means a better outcome.

The outcome is reported for subjects who received the Edwards Pericardial Aortic Bioprosthesis Model 11000A device in the pulmonary position where data is available.

Number of early adverse events occurring within 30 days of procedure divided by the total number of enrolled subjects times 100.

The outcome is reported for subjects who received the Edwards Pericardial Aortic Bioprosthesis Model 11000A device in the pulmonary position where data is available.

Late patient years are calculated from 31 days post-implant to the date of the last follow-up visit (or contact) or adverse event. Late patient year calculation: [(Number of late events/sum of late patient years) x 100]

The outcome is reported for subjects who received the Edwards Pericardial Aortic Bioprosthesis Model 11000A in the pulmonary position where data is available.

Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation/leak (a better outcome) and 4 represents severe regurgitation/leak (a worse outcome).

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation (a better outcome) and 4 represents severe regurgitation (a worse outcome).

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

Tricuspid regurgitation (TR) gradient (peak systolic) is defined as the maximum value measured of blood flowing back through the tricuspid valve during systole as measured in millimeters of mercury. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

Peak velocity is defined as the maximum speed in meters per second that the blood is flowing through the pulmonic heart valve in a given direction. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

The Doppler Velocity Index (DVI) is a calculation of the ratio of the sub valvular velocity obtained by pulse wave Doppler and the maximum velocity obtained by continuous wave Doppler across the prosthetic valve, i.e. Time velocity interval (TVI) of the pulmonic valve / TVI of the RVOT. There are no normal ranges issued by the American Society of Echocardiography's Guidelines and Standards Committee for the pulmonary valve, however the expectation is that DVI should remain relatively steady over time but will generally decrease as the degree of stenosis (narrowing or constriction of the valve opening) worsens.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

Transvalvular regurgitation velocity time interval (VTI) is defined as the measurement in centimeters of the blood flowing backwards through the tricuspid valve, averaged over time. There are no defined normal ranges for VTI. The VTI value is dependent on the function of the right ventricle of the heart (chamber within the heart that is responsible for pumping oxygen-depleted blood to the lungs) and the expectation is the value should be relatively steady over time.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

The New York Heart Association (NYHA)/Modified Ross functional classification system relates symptoms to everyday activities and the patient's quality of life.

Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, shortness of breath.

Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath.

Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or shortness of breath.

Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Changes in NYHA/Modified Ross HF classification from the preoperative baseline to the respective completed follow-up visits are shown as the number of subjects in each class who improved, worsened, or stayed the same.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data. NYHA was performed for subjects ≥13 years and the Modified Ross was performed for subjects ≤12 years. The following subjects converted to NYHA from Ross at the follow-up visit(s) due to meeting the age criteria: #6 at 5 Year, #7 at 5 Year, #13 at 4 Year and 5 Year, #22 at 3 Year, 4 Year and 5 Year.

Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection. The normal reference range for WBC count is 4.5 to 10.0 10^3 cells/microliters. In general, results either lower or higher than the normal range can indicate something is wrong.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

The red blood cell (RBC) count is a test that measures the number of oxygen-carrying blood cells in your blood. The red blood cell count normal range for women is 4.2 to 5.4 10^6 cells/microliters and for men is 4.7 to 6.1 10^6 cells/microliters. A high red blood cell count may indicate that you have a condition that's preventing you from getting enough oxygen. A low RBC may be caused by an infection, or a medical condition related to anemia. In general, results either lower or higher than the normal range can indicate something is wrong.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

This is the laboratory analysis of Hemoglobin count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells. In males, a healthy hemoglobin level is between 13.2 and 16.6 g/dL. In females, a hemoglobin count of between 11.6 and 15 g/dL is considered normal and healthy. In general, results either lower or higher than the normal range can indicate something is wrong.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

This is laboratory analysis of Hematocrit percentage on blood drawn from subjects. A hematocrit test measures the proportion of red blood cells in your blood. Red blood cells carry oxygen throughout your body. Having too few or too many red blood cells can be a sign of certain diseases. Normal hematocrit ranges for adult females are 36% to 44% and for adult males are 41% to 50%. In general, results either lower or higher than the normal range can indicate something is wrong.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

This is laboratory analysis of Platelet count on blood drawn from subjects. The purpose of platelets is to create hemostasis, which is the prevention of hemorrhaging (bleeding) and the process of keeping blood inside the vessel walls. A normal platelet range is 150 to 450 10^3 cells/microliter. In general, results either lower or higher than the normal range can indicate something is wrong.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.

The lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues. Normal levels of LDH in the blood can vary depending on the lab, but usually range between 140 units per liter (U/L) to 280 U/L for adults and tend to be higher for children and teens.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data. The protocol allowed subjects to have the option of having a serum LDH test or plasma free hemoglobin test or a haptoglobin test at each timeframe. Not all three tests were required for the subject.

Laboratory Analysis of Plasma Free Hemoglobin (Hgb) of blood drawn from subject. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood). The reference range for plasma free hemoglobin is 0.0 to 15.2 mg/dL. In general, values higher than this can indicate something is wrong.

This outcome is reported for subjects who received the trial valve. Note that the number of participants analyzed is different from that in the participant flow as there was some missing data. The protocol allowed subjects to have the option of having a serum LDH test or plasma free hemoglobin test or a haptoglobin test at each timeframe. Not all three tests were required for the subject.

The INR is a calculation based on results of a prothrombin time (PT). The PT is a blood test that measures the time it takes for the liquid portion (plasma) of the blood to clot. The normal range of INR depends on the patient. If they are not on an anticoagulant therapy, then the normal range is 0.9 - 1.1 and if they are on anticoagulant therapy then the normal range is 2 - 3.

This outcome is reported for subjects who received the trial valve who were on anticoagulant therapy during the trial. Note that only three of the 26 total participants were on anticoagulant therapy and that the number of participants analyzed is different from that in the participant flow as there was also some missing data.

Urobilinogen is a substance that is produced when bilirubin, a waste product produced by the breakdown of red blood cells, is processed in the liver and released into the intestine. The normal range of urobilinogen is less than 1 mg/dL. It is common to have values within the 0 to 8 mg/dL range. In general, results either lower or higher than the normal range can indicate something is wrong.

This outcome is reported for subjects who received the trial valve and required the urine urobilinogen clinical test. There were no subjects in the trial who required this clinical test.